| 摘要 |
Described are a carboxylic acid amide derivatives of formula (I), where both of -(CHR1)m-and -(CHR2)n-are-CH2-CH2-group adjacent to V and U groups form together with one or more identical or different and other hetero-CH= and/or -CH2-groups of four to seven-membered homo-or heterocyclic ring being optionally substituted by oxo, tioxo, methyl or trifluoromethyl, preferably morpholine, pyrrole, pyrrolidine, oxo-or tioxo-pyrrolidine , pyrazole, pyrazolidin, imidazole, imidazolidin, oxo-or tioxo or imidazolidin-imidazole, 1,4-oxazine, oxazole, oxazolidine, oxo-or tioxo-oxazolidine, or 3-oxo-1,4-oxazine ring, X is-CO-group, W is-CO-, -CH2- or -CH(-alkyl)-group, where alkyl is C1-C4alkylgroup, Y is an oxygen atom, as well C4alkylen-C1, C2-C4alkinylen, cycloalkylene, aminocarbonyl, -NH-,-N (alkyl)-, -CH2O-, -CH (OH)-, -OCH2-group, where alkyl is C1-C4alkylgroup, Z is a hydrogen atom or a halogen atom, nitro, amino, C1-C4 alkyl, C1-C4alkoxygroup, cyano, trifluoromethyl, hydroxyl or carboxyl, and their optical antipodes or racemates and/or their pharmaceutically acceptable salts formed with acids and bases, and pharmaceutical compositions containing carboxylic acid amide compound of formula (I) or optical antipodes or racemates or salts as active ingredients. Described are also methods for preparing carboxylic acid amide compounds of formula (I) and production of medicinal pharmaceutical composition containing these compounds. Carboxylic acid amide derivatives of formula (I) are highly active and selective NMDA receptor antagonists, and most of these compounds are selective antagonists of NR2B subtype NMDA receptor.
|
